Monday, July 26, 2021 Daily Archives

Samsung Biologics to manufacture Kineta’s antibody immunotherapy

by

Korean CDMO Samsung Biologics will develop and provide manufacturing services to support IND filing for Kineta’s anti-VISTA antibody candidate. Contract development manufacturing organization (CDMO) Samsung Biologics has signed a partnership agreement to provide end-to-end services for Kineta’s anti-V-domain immunoglobulin suppressor of T cell activation (anti-VISTA) candidate KVA12.1, which aims to treat solid tumors. Preclinical studies have shown KVA12.1 to have single agent anti-tumor activity and that targeting VISTA along with programmed cell death-1 (PD-1), PD ligand 1 (PD-L1), or cytotoxic…

July 26, 2021

With $100m in hand, Kriya set to bring GMP gene therapy plant online

by

Kriya Therapeutics will use $100 million from a Series B funding to develop its gene therapy manufacturing platforms and says its GMP plant in North Carolina will come online this year. The Series B financing – led by Patient Square Capital, with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others – closed earlier this month. The funding will help support Kriya’s gene therapy platforms and manufacturing infrastructure, which aim to reduce the cost of…

July 26, 2021

From baking to bioprocessing: Lumen leases Seattle plant to advance ‘edible’ antibodies

by

Spirulina-based antibody developer Lumen Biosciences will convert a bakehouse into a biologics plant capable of producing 15 kg per week of cGMP-grade drug substance. Seattle, Washington-based Lumen turns spirulina – protein-rich cyanobacteria touted by many health enthusiasts as a ‘superfood’ – into tiny factories that churn out therapeutic antibodies. To support the development of its candidates, the firm has expanded its manufacturing footprint by leasing a former bakery in the Fremont-Wallingford neighborhood of Seattle. “All of our current products are…

July 26, 2021